Etop Ibcsg Partners Foundation

This study tested a combination of two immunotherapy drugs (atezolizumab and bevacizumab) plus chemotherapy in 95 people with a specific type of advanced lung cancer (EGFR-mutant non-small cell) that had stopped responding to standard targeted pills. The goal was to see if this n…

This study tested whether adding the immunotherapy drug atezolizumab to standard treatment (bevacizumab plus chemotherapy) helps people with advanced malignant pleural mesothelioma live longer. The trial involved 400 adults whose cancer could not be removed by surgery. Researcher…

This study tested whether adding bevacizumab to osimertinib helps people with advanced lung cancer that has a specific genetic change (EGFR and T790M mutations). 155 adults who had already tried other treatments took part. The main goal was to see if the combination slowed cancer…

This study looked at whether shutting down the ovaries (ovarian suppression) and adding a drug called exemestane could better prevent breast cancer from coming back in premenopausal women with hormone-sensitive breast cancer. Over 3,000 women who had surgery took either tamoxifen…

This study tested whether a combination of two hormone-blocking drugs (exemestane and triptorelin) works better than the standard treatment (triptorelin and tamoxifen) for premenopausal women with hormone-sensitive breast cancer. Over 2,600 women who had surgery to remove their c…

This study tested a new drug called giredestrant, alone or with triptorelin, against a standard treatment (anastrozole plus triptorelin) in 231 premenopausal women with early-stage, hormone-sensitive breast cancer. The goal was to see how well the drugs slow tumor growth before s…